Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model

UNC Libraries(2020)10.17615/5rca-2e42Source: DataRank Database

HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model is a research paper published in UNC Libraries (2020). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.00)OA: greenTopics (47)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Craig Sykes,Leila Remling‐Mulder,Ramesh Akkina ORCID,Milena Veselinović ORCID,Angela D. M. Kashuba ORCID

Live enrichment

PubMed:21097893 OpenAlex:https://openalex.org/W4298869621

National Institutes of Health

Grant: 5P30AI050410-05

UNC Center for Aids Research

National Institutes of Health

Grant: 1R56AI095101-01A1

Efficacy Testing of HIV-Specific Microbicides in Humanized Mice

National Institutes of Health

Grant: 1R01AI100845-01

Modeling Next Generation HIV PrEP in Humanized Mice

FWCI

0.00

Citation Percentile

0.2%

greenLicense: Elsevier Non-Commercial

repositoryhttps://doi.org/10.17615/5rca-2e42

https://doi.org/10.1016/j.virol.2014.07.008

https://dx.doi.org/10.17615/8q6z-mz05

https://dx.doi.org/10.17615/5rca-2e42

https://pubmed.ncbi.nlm.nih.gov/25105490

Fields of Study

HIV Research and TreatmentHIV/AIDS drug development and treatmentHIV-related health complications and treatments0301 basic medicine03 medical and health sciences0303 health sciences

Keywords

MaravirocTenofovirEntry inhibitorPharmacologyHuman immunodeficiency virus (HIV)DrugHumanized mouseDistribution (mathematics)VirologyProtease inhibitor (pharmacology)TNF inhibitorCCR5 receptor antagonistPre-exposure prophylaxisMedicineImmunologyViral loadVirusViral entryViral replicationTumor necrosis factor alphaAntiretroviral therapyChemokine receptorHIV pre-exposure prophylaxis in hu-miceAnti-HIV AgentsOrganophosphonatesHIV InfectionsAnti-retroviral drug pharmacokinetics in humanized miceHumanized mice for HIV PrEP PK studiesMiceCyclohexanesAnimalsHumansMucous MembraneAdenineTriazolesVirus InternalizationTenofovir and maraviroc phamacokinetics in hu-miceDisease Models, AnimalHIV-1Reverse Transcriptase InhibitorsFemale

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being